+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Preclinical CRO Market - Global Forecast 2026-2032- Product Image
Preclinical CRO Market - Global Forecast 2026-2032- Product Image
Sale

Preclinical CRO Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5454997
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Preclinical CRO Market is projected to reach USD 7.61 Billion in 2026. It is expected to continue growing at a CAGR of 8.93%, reaching USD 12.76 Billion by 2032.

The preclinical CRO market is central to how pharmaceutical, biotechnology, and academic sponsors convert validated biology into investigational new drug, or IND, packages. Demand is anchored by regulated GLP toxicology, safety pharmacology, ADME/DMPK, bioanalysis, efficacy models, pathology, and CMC-adjacent analytical support required before first-in-human studies.

Growth is supported by sustained biomedical R&D spending, expanding biologics and advanced therapy pipelines, and the need for specialized infrastructure that many sponsors do not maintain in-house. Regulatory frameworks from the FDA, EMA, ICH, OECD, and national GLP authorities continue to make quality systems, data integrity, animal welfare, and translational relevance decisive differentiators for preclinical CRO partners.

Transformative Shifts in the Preclinical CRO Landscape

The preclinical CRO landscape is shifting from capacity-based outsourcing toward science-led, integrated development partnerships. Sponsors increasingly expect CROs to combine disease biology, model selection, toxicology strategy, biomarker development, bioanalytical validation, and regulatory documentation into a coordinated IND-enabling pathway.

Important structural changes include growth in biologics, cell and gene therapies, RNA-based medicines, radiopharmaceuticals, and complex immunology programs. The FDA Modernization Act 2.0 removed the statutory requirement that animal testing be used in every drug-development case, increasing attention on validated new approach methodologies while preserving the need for regulator-accepted evidence packages. This shift is accelerating interest in organ-on-chip systems, in silico toxicology, high-content imaging, and human-relevant translational models.

Cumulative Impact of Artificial Intelligence on Preclinical CROs

Artificial intelligence is changing preclinical CRO operations through target validation, compound prioritization, image analysis, pathology support, toxicology prediction, literature mining, dose optimization, and protocol design. These applications can reduce avoidable iteration when they are paired with curated datasets, domain expertise, audit trails, and human scientific review.

The cumulative impact is not the replacement of GLP studies, but a more evidence-rich design process. Regulators, including the FDA and EMA, have emphasized transparency, model governance, bias control, cybersecurity, traceability, and fit-for-purpose validation for AI-enabled tools. CROs that align AI with validated workflows, secure data environments, and quality management systems are better positioned to improve study reliability, reproducibility, and sponsor confidence.

Key Regional Insights for Preclinical CRO Services

North America remains a core preclinical CRO hub because the United States has deep venture financing, large pharmaceutical R&D operations, major academic medical centers, established GLP testing capacity, and direct proximity to FDA expectations. Canada contributes translational science, clinical research infrastructure, public life sciences programs, and cross-border collaboration with U.S. sponsors.

Europe is shaped by EMA coordination, national competent authorities, strong GLP laboratories, animal welfare regulation, and established pharmaceutical clusters in Germany, France, the United Kingdom, Italy, and Spain. Asia-Pacific is expanding through China, India, Japan, South Korea, Australia, and ASEAN countries, supported by cost-efficient operations, maturing regulatory systems, chemistry and biologics capabilities, and rising domestic innovation. Latin America is developing through Brazil and Mexico, where healthcare demand, local manufacturing policies, and academic research networks support regional service opportunities. The Middle East is building biotechnology and healthcare research capacity through national diversification agendas, particularly in Gulf economies, while Africa is gradually strengthening biomedical research infrastructure through public health research, university partnerships, and disease-area specialization.

Key Economic and Strategic Group Insights

Within ASEAN, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and the Philippines support regional life sciences growth through manufacturing investment, university research, improving clinical ecosystems, and regulatory modernization. Singapore is especially important for biomedical research coordination, while larger ASEAN markets contribute patient access, manufacturing depth, and expanding scientific talent. The GCC is building healthcare and biotechnology capacity through national diversification strategies, with Saudi Arabia and the United Arab Emirates emphasizing research infrastructure, advanced medicine access, genomics initiatives, and public-private health innovation.

The European Union benefits from harmonized regulatory pathways, Horizon Europe funding, high pharmacovigilance standards, data protection requirements, and strong quality expectations that influence preclinical CRO vendor qualification. BRICS countries add scale, scientific talent, chemistry capabilities, and growing domestic demand, with China, India, and Brazil especially relevant to outsourcing, manufacturing, and translational research. The G7 continues to anchor high-value innovation, intellectual property protection, mature regulatory systems, and advanced biomedical funding. NATO markets provide resilient research supply chains for allied healthcare priorities, although preclinical testing, GLP oversight, and drug development requirements remain governed by national and regional regulators.

Key Country Insights Across Major Preclinical CRO Markets

The United States leads through FDA-regulated development pathways, biotech financing, academic discovery networks, and large-scale outsourcing demand. Canada offers translational research and clinical connectivity, while Mexico and Brazil support regional access, manufacturing links, and expanding life sciences investment. The United Kingdom remains influential through MHRA expertise, the Golden Triangle research base, advanced therapy development, and strong university-industry collaboration.

Germany, France, Italy, and Spain provide strong pharmaceutical manufacturing, toxicology, bioanalysis, and academic ecosystems supported by national research institutions and EU-aligned quality expectations. Russia retains scientific capacity but faces market-access, logistics, and sanctions-related constraints that affect international collaboration. China and India are major growth engines through scale, medicinal chemistry, biologics, biosimilars, and cost-effective service capacity, while Japan, South Korea, and Australia contribute high-quality regulatory science, innovation incentives, advanced biomedical research, and specialized preclinical capabilities. South Korea is notable for biologics and cell therapy infrastructure, Japan for rigorous regulatory science and pharmaceutical innovation, and Australia for translational research networks and globally recognized study quality.

Actionable Recommendations for Industry Leaders

Industry leaders should select preclinical CRO partners based on scientific relevance, GLP compliance history, data integrity controls, animal welfare standards, model validity, and regulatory writing capability rather than cost alone. Early alignment on ICH M3(R2), safety pharmacology, genetic toxicology, reproductive toxicology, immunogenicity, bioanalytical methods, and species selection can prevent costly protocol redesign.

Executives should also build dual-source capacity for critical assays, qualify AI-enabled workflows, and require transparent study governance. Strategic CRO relationships should include milestone-based oversight, quality audits, cybersecurity requirements, biomarker strategy, sample-chain controls, and escalation procedures for unexpected findings. Sponsors that integrate CROs earlier in candidate selection can improve IND readiness, strengthen translational rationale, and reduce avoidable development risk.

Research Methodology and Evidence Base

This executive summary is built from verified public and industry sources, including regulatory guidance from the FDA, EMA, ICH, OECD GLP principles, national agency publications, clinical trial registries, scientific literature, public policy documents, and recognized life sciences reports. Insights were triangulated across regulatory, scientific, operational, and regional indicators.

The analysis prioritizes evidence that is observable and reproducible, including R&D investment patterns, therapeutic modality shifts, outsourcing drivers, quality-system expectations, AI governance principles, and regional capability development. No unsupported market estimates are used; emphasis is placed on documented regulatory changes, established preclinical requirements, and validated operational trends affecting CRO decision-making.

Conclusion: Strategic Outlook for Preclinical CROs

The preclinical CRO market is becoming more specialized, regulated, and technology-enabled as sponsors pursue complex therapies under tighter development timelines. CROs that combine GLP execution, translational science, bioanalytical depth, animal welfare discipline, and regulatory fluency are positioned to remain essential partners in drug development.

Artificial intelligence, new approach methodologies, and globalized outsourcing will continue to reshape study design, but the market will still reward defensible evidence, quality systems, reproducibility, and regulator-ready documentation. Sponsors that choose CRO partners strategically can improve program resilience, accelerate IND preparation, and strengthen the probability of successful clinical transition.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Preclinical CRO Market, by Service Type
7.1. Introduction
7.2. Bioanalytical Services
7.2.1. LC-MS/MS Bioanalysis
7.2.2. Product Analysis
7.2.3. Stability Testing
7.2.4. Immunogenicity Testing
7.2.5. Pharmacokinetics & Pharmacodynamics Testing
7.3. In Vivo & In Vitro Studies
7.4. Toxicology Testing
7.4.1. General Toxicology
7.4.2. Safety Pharmacology
7.4.3. Reproductive Toxicology
7.4.4. Juvenile Toxicology
7.4.5. Carcinogenicity Studies
7.4.6. Clinical Pathology Services
7.5. Drug Discovery Services
7.5.1. Target ID & Validation
7.5.2. High-Throughput Screening
7.5.3. Fragment Screening
7.5.4. Functional Genomics (CRISPR)
7.6. Chemistry, Manufacturing, and Controls (CMC)
7.6.1. Formulation Development
7.6.2. Impurity Testing
7.6.3. GMP Manufacture & Packaging
7.6.4. Clinical Supply Logistics
8. Preclinical CRO Market, by Model Type
8.1. Introduction
8.2. Patient Derived Organoid (PDO) Model
8.3. Patient Derived Xenograft Model
9. Preclinical CRO Market, by Molecule Type
9.1. Introduction
9.2. Small Molecule
9.3. Large Molecule
10. Preclinical CRO Market, by Application
10.1. Introduction
10.2. Cardiology
10.3. Neurology
10.4. Oncology
10.5. Infectious Diseases
10.6. Metabolic Disorders
11. Preclinical CRO Market, by End User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Biotechnology Companies
11.4. Pharmaceutical Companies
12. Preclinical CRO Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Middle East
12.6. Africa
13. Preclinical CRO Market, by Group
13.1. NATO
13.2. G7
13.3. European Union
13.4. BRICS
13.5. ASEAN
13.6. GCC
14. Preclinical CRO Market, by Country
14.1. United States
14.2. China
14.3. Germany
14.4. Japan
14.5. United Kingdom
14.6. India
14.7. France
14.8. Australia
14.9. Canada
14.10. Brazil
14.11. Italy
14.12. Russia
14.13. Mexico
14.14. Spain
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Charles River Laboratories International, Inc.
16.2. Laboratory Corporation of America Holdings
16.3. ICON PLC
16.4. WuXi AppTec Co., Ltd.
16.5. Syneos Health, Inc.
16.6. Eurofins Scientific SE
16.7. Thermo Fisher Scientific Inc.
16.8. Evotec SE
16.9. Pharmaron Beijing Co., Ltd.
16.10. Medpace Holdings, Inc.
16.11. SGS SA
16.12. Inotiv, Inc.
16.13. Genesis Biotechnology Group, LLC
16.14. Jubilant Biosys Ltd.
16.15. 10x Genomics, Inc.
16.16. Celerion Holdings, Inc.
16.17. Taconic Biosciences, Inc.
16.18. Atuka Inc.
16.19. BenchSci
16.20. Diag2Tec SAS
16.21. Hera Biolabs Inc. by Demeetra AgBio, Inc.
16.22. ImQuest BioSciences Inc. by Statera Biopharma, Inc.
16.23. Intertek Group PLC
16.24. IQVIA Inc.
16.25. JSR Corporation
16.26. MLM Medical Labs GmbH
16.27. Phenos GmbH
16.28. REPROCELL Inc.
16.29. Scantox Holding Aps
16.30. SCiAN Services Inc.
List of Figures
FIGURE 1. GLOBAL PRECLINICAL CRO MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PRECLINICAL CRO MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PRECLINICAL CRO MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PRECLINICAL CRO MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PRECLINICAL CRO MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PRECLINICAL CRO MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL PRECLINICAL CRO MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PRECLINICAL CRO MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BIOANALYTICAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BIOANALYTICAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BIOANALYTICAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LC-MS/MS BIOANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LC-MS/MS BIOANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LC-MS/MS BIOANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PRODUCT ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PRODUCT ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PRODUCT ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL STABILITY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL STABILITY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL STABILITY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNOGENICITY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNOGENICITY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNOGENICITY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PHARMACOKINETICS & PHARMACODYNAMICS TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PHARMACOKINETICS & PHARMACODYNAMICS TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PHARMACOKINETICS & PHARMACODYNAMICS TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL IN VIVO & IN VITRO STUDIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL IN VIVO & IN VITRO STUDIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL IN VIVO & IN VITRO STUDIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GENERAL TOXICOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GENERAL TOXICOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL GENERAL TOXICOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SAFETY PHARMACOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SAFETY PHARMACOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SAFETY PHARMACOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL REPRODUCTIVE TOXICOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL REPRODUCTIVE TOXICOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL REPRODUCTIVE TOXICOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL JUVENILE TOXICOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL JUVENILE TOXICOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL JUVENILE TOXICOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CARCINOGENICITY STUDIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CARCINOGENICITY STUDIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CARCINOGENICITY STUDIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CLINICAL PATHOLOGY SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CLINICAL PATHOLOGY SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CLINICAL PATHOLOGY SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TARGET ID & VALIDATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TARGET ID & VALIDATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL TARGET ID & VALIDATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HIGH-THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HIGH-THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HIGH-THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL FRAGMENT SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL FRAGMENT SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL FRAGMENT SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL FUNCTIONAL GENOMICS (CRISPR) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL FUNCTIONAL GENOMICS (CRISPR) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL FUNCTIONAL GENOMICS (CRISPR) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL IMPURITY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL IMPURITY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL IMPURITY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL GMP MANUFACTURE & PACKAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL GMP MANUFACTURE & PACKAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL GMP MANUFACTURE & PACKAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CLINICAL SUPPLY LOGISTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CLINICAL SUPPLY LOGISTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CLINICAL SUPPLY LOGISTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PATIENT DERIVED ORGANOID (PDO) MODEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PATIENT DERIVED ORGANOID (PDO) MODEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PATIENT DERIVED ORGANOID (PDO) MODEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PATIENT DERIVED XENOGRAFT MODEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL PATIENT DERIVED XENOGRAFT MODEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL PATIENT DERIVED XENOGRAFT MODEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL LARGE MOLECULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL LARGE MOLECULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL LARGE MOLECULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL PRECLINICAL CRO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. EUROPE PRECLINICAL CRO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. EUROPE PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 129. EUROPE PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 130. EUROPE PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 131. EUROPE PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 132. EUROPE PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 133. EUROPE PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 134. EUROPE PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 135. EUROPE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 136. EUROPE PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. AFRICA PRECLINICAL CRO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. AFRICA PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 169. AFRICA PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 170. AFRICA PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 171. AFRICA PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 172. AFRICA PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 173. AFRICA PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 174. AFRICA PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 175. AFRICA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 176. AFRICA PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL PRECLINICAL CRO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 178. NATO PRECLINICAL CRO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. NATO PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 180. NATO PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 181. NATO PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 182. NATO PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 183. NATO PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 184. NATO PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 185. NATO PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 186. NATO PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 187. NATO PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. G7 PRECLINICAL CRO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. G7 PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 190. G7 PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 191. G7 PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 192. G7 PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 193. G7 PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 194. G7 PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 195. G7 PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 196. G7 PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 197. G7 PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. BRICS PRECLINICAL CRO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. BRICS PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 210. BRICS PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 211. BRICS PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 212. BRICS PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 213. BRICS PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 214. BRICS PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 215. BRICS PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 216. BRICS PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 217. BRICS PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. ASEAN PRECLINICAL CRO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 219. ASEAN PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 220. ASEAN PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 221. ASEAN PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 222. ASEAN PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 223. ASEAN PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 224. ASEAN PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 225. ASEAN PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 226. ASEAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 227. ASEAN PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. GCC PRECLINICAL CRO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. GCC PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 230. GCC PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 231. GCC PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 232. GCC PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 233. GCC PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 234. GCC PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 235. GCC PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 236. GCC PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 237. GCC PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 238. GLOBAL PRECLINICAL CRO MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 247. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 248. UNITED STATES PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. CHINA PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. CHINA PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 251. CHINA PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 252. CHINA PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 253. CHINA PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 254. CHINA PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 255. CHINA PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 256. CHINA PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 257. CHINA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 258. CHINA PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. GERMANY PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. GERMANY PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 261. GERMANY PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 262. GERMANY PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 263. GERMANY PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 264. GERMANY PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 265. GERMANY PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 266. GERMANY PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 267. GERMANY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 268. GERMANY PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. JAPAN PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. JAPAN PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 271. JAPAN PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 272. JAPAN PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 273. JAPAN PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 274. JAPAN PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 275. JAPAN PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 276. JAPAN PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 277. JAPAN PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 278. JAPAN PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. INDIA PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. INDIA PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 291. INDIA PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 292. INDIA PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 293. INDIA PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 294. INDIA PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 295. INDIA PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 296. INDIA PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 297. INDIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 298. INDIA PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. FRANCE PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. FRANCE PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 301. FRANCE PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 302. FRANCE PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 303. FRANCE PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 304. FRANCE PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 305. FRANCE PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 306. FRANCE PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 307. FRANCE PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 308. FRANCE PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. AUSTRALIA PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 311. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 312. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 313. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 314. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 315. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 316. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 317. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 318. AUSTRALIA PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 319. CANADA PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. CANADA PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 321. CANADA PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 322. CANADA PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 323. CANADA PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 324. CANADA PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 325. CANADA PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 326. CANADA PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 327. CANADA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 328. CANADA PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 329. BRAZIL PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 330. BRAZIL PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 331. BRAZIL PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 332. BRAZIL PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 333. BRAZIL PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 334. BRAZIL PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 335. BRAZIL PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 336. BRAZIL PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 337. BRAZIL PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 338. BRAZIL PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. ITALY PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 340. ITALY PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 341. ITALY PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 342. ITALY PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 343. ITALY PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 344. ITALY PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 345. ITALY PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 346. ITALY PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 347. ITALY PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 348. ITALY PRECLINICAL CRO MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 349. RUSSIA PRECLINICAL CRO MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 350. RUSSIA PRECLINICAL CRO MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 351. RUSSIA PRECLINICAL CRO MARKET SIZE, BY BIOANALYTICAL SERVICES, 2017-2032 (USD MILLION)
TABLE 352. RUSSIA PRECLINICAL CRO MARKET SIZE, BY TOXICOLOGY TESTING, 2017-2032 (USD MILLION)
TABLE 353. RUSSIA PRECLINICAL CRO MARKET SIZE, BY DRUG DISCOVERY SERVICES, 2017-2032 (USD MILLION)
TABLE 354. RUSSIA PRECLINICAL CRO MARKET SIZE, BY CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC), 2017-2032 (USD MILLION)
TABLE 355. RUSSIA PRECLINICAL CRO MARKET SIZE, BY MODEL TYPE, 2017-2032 (USD MILLION)
TABLE 356. RUSSIA PRECLINICAL CRO MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 357. RUSSIA PRECLINICAL CRO MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 358. RUSSIA PREC

Companies Mentioned

  • Charles River Laboratories International, Inc.
  • Laboratory Corporation of America Holdings
  • ICON PLC
  • WuXi AppTec Co., Ltd.
  • Syneos Health, Inc.
  • Eurofins Scientific SE
  • Thermo Fisher Scientific Inc.
  • Evotec SE
  • Pharmaron Beijing Co., Ltd.
  • Medpace Holdings, Inc.
  • SGS SA
  • Inotiv, Inc.
  • Genesis Biotechnology Group, LLC
  • Jubilant Biosys Ltd.
  • 10x Genomics, Inc.
  • Celerion Holdings, Inc.
  • Taconic Biosciences, Inc.
  • Atuka Inc.
  • BenchSci
  • Diag2Tec SAS
  • Hera Biolabs Inc. by Demeetra AgBio, Inc.
  • ImQuest BioSciences Inc. by Statera Biopharma, Inc.
  • Intertek Group PLC
  • IQVIA Inc.
  • JSR Corporation
  • MLM Medical Labs GmbH
  • Phenos GmbH
  • REPROCELL Inc.
  • Scantox Holding Aps
  • SCiAN Services Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.61 Billion
Forecasted Market Value ( USD ) by 2032 $ 12.76 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

In Vivo CRO Market - Global Forecast 2026-2032 - Product Image

In Vivo CRO Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Oncology Based In-Vivo CRO Market - Global Forecast 2026-2032 - Product Image

Oncology Based In-Vivo CRO Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
In Vivo Contract Research Organization (CRO) - Global Strategic Business Report - Product Image

In Vivo Contract Research Organization (CRO) - Global Strategic Business Report

  • Report
  • 220 Pages
  • Global
From
Preclinical CRO Market Size, Share & Trends Analysis Report by Service, Development Stage, Indication, Model, End Use, Region, and Growth Forecasts, 2026-2033 - Product Image

Preclinical CRO Market Size, Share & Trends Analysis Report by Service, Development Stage, Indication, Model, End Use, Region, and Growth Forecasts, 2026-2033

  • Report
  • 120 Pages
  • Global
From
Preclinical CRO Market Size, Share, Trends, and Forecast by Service, End Use, and Region, 2026-2034 - Product Image

Preclinical CRO Market Size, Share, Trends, and Forecast by Service, End Use, and Region, 2026-2034

  • Report
  • 143 Pages
  • Global
From

About the Preclinical CRO Market

The Preclinical CRO market is a subset of the Drug Discovery industry, focusing on the preclinical stages of drug development. Preclinical CROs provide services such as drug safety testing, pharmacology studies, and toxicology studies. These services are used to assess the safety and efficacy of potential drugs before they are tested in humans. Preclinical CROs also provide services such as drug metabolism and pharmacokinetics, which are used to understand how a drug is absorbed, distributed, metabolized, and eliminated in the body. Preclinical CROs are an important part of the drug discovery process, as they provide the data needed to move a drug candidate forward in the development process. Preclinical CROs are also used to reduce the cost and time associated with drug development, as they can provide the data needed to make decisions quickly and efficiently. Some companies in the Preclinical CRO market include Charles River Laboratories, WuXi AppTec, Covance, PRA Health Sciences, and Envigo. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.